Movement Disorders (revue) - Curation (Istex)

Index « Keywords » - entrée « neuroprotection »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
neuroplasticity < neuroprotection < neuroprotective  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 28.
[0-20] [0 - 20][0 - 28][20-27][20-40]
Ident.Authors (with country if any)Title
000019 (2002) Johannes Schiefer [Allemagne] ; G. Bernhard Landwehrmeyer [Allemagne] ; Hans-Gerd Lüesse [Allemagne] ; Arne Sprünken [Allemagne] ; Christiane Puls [Allemagne] ; Anna Milkereit [Allemagne] ; Eva Milkereit [Allemagne] ; Christoph M. Kosinski [Allemagne]Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
000099 (2011) Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis]Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
000114 (2005) Robert M. Silva [États-Unis] ; Chia-Yi Kuan [États-Unis] ; Pasko Rakic [États-Unis] ; Robert E. Burke [États-Unis]Mixed lineage kinase–c‐jun N‐terminal kinase signaling pathway: A new therapeutic target in Parkinson's disease
000169 (2004) Carl E. Clarke [Royaume-Uni]A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs?
000190 (2004) Tomás González-Hernández [Espagne] ; Pedro Barroso-Chinea [Espagne] ; Manuel Rodríguez [Espagne]Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat
000270 (2008) C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
000278 (2001) Krishna P. Datla [Royaume-Uni] ; Stavia B. Blunt [Royaume-Uni] ; David T. Dexter [Royaume-Uni]Chronic L‐DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6‐OHDA or FeCl3 nigrostriatal lesions
000298 (2011) Martin Köllensperger [Autriche] ; Florian Krismer [Autriche] ; Anton Pallua [Autriche] ; Nadia Stefanova [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy
000327 (2009) Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël]Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
000507 (2007) Kjell Fuxe [Suède] ; Daniel Marcellino [Suède] ; Susanna Genedani [Italie] ; Luigi Agnati [Italie]Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease
000614 (2009) Robert G. Hart [États-Unis] ; Lesly A. Pearce [États-Unis] ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis]Neuroprotection trials in Parkinson's disease: Systematic review
000678 (2011) Jose Luis L Pez-Send N [Espagne] ; Ana Royuela [Espagne] ; Patricia Trigo [Espagne] ; Michael Orth [Allemagne] ; Herwig Lange [Allemagne] ; Ralf Reilmann [Allemagne] ; Jennifer Keylock [Royaume-Uni] ; Hugh Rickards [Royaume-Uni] ; Silvia Piacentini [Italie] ; Ferdinando Squitieri [Italie] ; Bernhard Landwehrmeyer [Allemagne] ; Marie-Noelle Witjes-Ane [Pays-Bas] ; Caroline. K. Jurgens [Pays-Bas] ; Raymund. A. C. Roos [Pays-Bas] ; Victor Abraira [Espagne] ; Justo. G. De Yébenes [Espagne]What is the impact of education on Huntington's disease?
000680 (2011) Anthony E. Lang [Canada]A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials
000847 (2008) Carl E. Clarke [Royaume-Uni]Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
000932 (2011) Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada]Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study
000A89 (2008) Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis]Nicotine and Parkinson's disease: Implications for therapy
000C31 (2003) Paul K. Morrish [Royaume-Uni]How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
000E02 (2010) Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis]Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
000E65 (2007) Anthony H. V. Schapira [Royaume-Uni]Future directions in the treatment of Parkinson's disease
001026 (2002) Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France]Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence
001497 (2002) Robert A. Hauser [États-Unis] ; Nicholas H. G. Holford [Nouvelle-Zélande]Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/KwdEn.i -k "neuroprotection" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/KwdEn.i  \
                -Sk "neuroprotection" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    neuroprotection
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024